Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors

Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors

Background Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 mont...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2023-06, Vol.163 (2), p.327-338
Hauptverfasser: Biswas, Archita, Salvucci, Manuela, Connor, Kate, Düssmann, Heiko, Carberry, Steven, Fichtner, Michael, King, Ellen, Murphy, Brona, O’Farrell, Alice C., Cryan, Jane, Beausang, Alan, Heffernan, Josephine, Cremona, Mattia, Hennessy, Bryan T., Clerkin, James, Sweeney, Kieron J., MacNally, Steve, Brett, Francesca, O’Halloran, Philip, Bacon, Orna, Furney, Simon, Verreault, Maite, Quissac, Emie, Bielle, Franck, Ahmed, Mohammed H., Idbaih, Ahmed, Leenstra, Sieger, Ntafoulis, Ioannis, Fabro, Federica, Lamfers, Martine, Golebiewska, Anna, Hertel, Frank, Niclou, Simone P., Yen, Romain Tching Chi, Kremer, Andreas, Dilcan, Gonca, Lodi, Francesca, Arijs, Ingrid, Lambrechts, Diether, Purushothama, Manasa Kalya, Kel, Alexander, Byrne, Annette T., Prehn, Jochen H.M.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Apoptosis
Brain
Brain - pathology
Brain cancer
Brain Neoplasms
Brain Neoplasms - pathology
Cell cycle
Cilia
Comparative analysis
Glioblastoma
Glioblastoma - pathology
Human health and pathology
Humans
Life Sciences
Medicine
Medicine & Public Health
Neurology
Oncology
Prognosis
Protein arrays
Raf protein
Survivors
Therapeutic targets
Transcription factors
Transcriptomics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 months, Long term survivors, LTS). Methods Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age 
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-023-04341-3